Last reviewed 2026-04-23 · How we verify

CsA eye gel

Calcineurin inhibitor

Calcineurin inhibitor Used for Keratitis, Uveitis.

At a glance

Mechanism of action

CsA works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes.

Approved indications

• Keratitis
• Uveitis

Common side effects

• Eye irritation
• Blurred vision
• Eye pain

Key clinical trials

• SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
• A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease (PHASE3)
• A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients (PHASE3)
• Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users (PHASE3)
• Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease (PHASE3)
• Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease (PHASE4)
• Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye (PHASE2)
• Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CsA eye gel CI brief — competitive landscape report
• CsA eye gel updates RSS · CI watch RSS
• Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. portfolio CI